Mirko von Hein

Health economist helping you succeed in HEOR, market access & life sciences

NICE

Apr 6, 2026

•

5 min read

NICE Conference 2026: What Was Said, What It Means, and Whether to Be Optimistic

A new chief exec, a QALY debate that won't go away, and the moment NICE and the MHRA finally got in the same room.

Mirko von Hein

Career Advice

The Pharma Job Market Is the Worst in 32 Years. A Veteran Recruiter Explains Why

Mar 30, 2026

•

6 min read

The Pharma Job Market Is the Worst in 32 Years. A Veteran Recruiter Explains Why

Grant Coren on hiring freezes, AI screening, ageism, and what it really takes to land a role in life sciences right now

Mirko von Hein

Tools & Productivity

You're Doing Expert Elicitation Wrong (And So Was I)

Mar 23, 2026

•

3 min read

You're Doing Expert Elicitation Wrong (And So Was I)

What defensible expert elicitation actually looks like — and a tool that makes it possible

Mirko von Hein

Tools & Productivity

My Tech Stack as a Health Economist & YouTuber

Mar 2, 2026

•

3 min read

My Tech Stack as a Health Economist & YouTuber

One of the most common questions I get is about my tech stack — so here's everything I use for health economics work and running The Pharma Perspective podcast.

Mirko von Hein

Career Advice

The Skill That Matters More Than Expertise: What a Pharma VP Learned in 25 Years

Feb 17, 2026

•

9 min read

The Skill That Matters More Than Expertise: What a Pharma VP Learned in 25 Years

A Conversation with Peter Wickersham, Vice President & General Manager of a Major UK Pharma Affiliate

Mirko von Hein

Market Access

The UK's Innovation Dilemma: Is Britain Pricing Itself Out of the Medicine Market?

Feb 16, 2026

•

6 min read

The UK's Innovation Dilemma: Is Britain Pricing Itself Out of the Medicine Market?

The UK spends significantly less of its health budget on branded medicines than comparable nations. Termination rates in the appraisal process have doubled. And companies are increasingly choosing not to launch here at all. A conversation with the ABPI's Jack Neill-Hall about what's at stake—and where the opportunity lies.

Mirko von Hein

Patient-Reported Outcomes (PRO)

Feb 9, 2026

•

4 min read

The Patient Voice is Still Underused

Bridging the Gap Between Endpoints, HTA, and Lived Experience

Mirko von Hein

Pharmaceutical Policy

Why Karl Claxton Warned Against the NICE Threshold Change (And Why It Happened Anyway)

Feb 8, 2026

•

7 min read

Why Karl Claxton Warned Against the NICE Threshold Change (And Why It Happened Anyway)

The Warning That Went Unheeded

Mirko von Hein

Systematic Literature Review

Responsibility, Risk, and the Future of Evidence

Feb 7, 2026

•

4 min read

Responsibility, Risk, and the Future of Evidence

What building a HEOR consultancy during COVID reveals about leadership, judgment, and where our field is heading

Mirko von Hein

Drug Regulation

Feb 6, 2026

•

4 min read

Rethinking Medicines, Evidence & Power

Lessons from My Conversation with Prof. Jerry Avorn

Mirko von Hein

Mirko von Hein

NICE Conference 2026: What Was Said, What It Means, and Whether to Be Optimistic

The Pharma Job Market Is the Worst in 32 Years. A Veteran Recruiter Explains Why

You're Doing Expert Elicitation Wrong (And So Was I)

My Tech Stack as a Health Economist & YouTuber

The Skill That Matters More Than Expertise: What a Pharma VP Learned in 25 Years

The UK's Innovation Dilemma: Is Britain Pricing Itself Out of the Medicine Market?

The Patient Voice is Still Underused

Why Karl Claxton Warned Against the NICE Threshold Change (And Why It Happened Anyway)

Responsibility, Risk, and the Future of Evidence

Rethinking Medicines, Evidence & Power

The HEOR Intel You Actually Need

Tracking what matters in HEOR, market access, and pharma consulting for your career success